

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 6-K

**Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934**

Date of Report: 05/11/2022

Commission File Number: 001-39777

Nanobiotix S.A.
(Exact Name of Registrant as Specified in its Charter)

**60 Rue de Wattignies
75012 Paris, France
(Address of principal executive office)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

EXHIBIT INDEX

Exhibit Title

[99.1](#) [Press Release, dated May 11, 2022](#)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

PORTER NOVELLI
(Agency)

By: /s/ Emily Papp

Emily Papp
Account Supervisor

NANOBIOTIX S.A.
(Registrant)

By: /s/ Bart Van Rhijn

Bart Van Rhijn
Chief Financial Officer

NANOBIOTIX to Participate in Two Upcoming Investor Conferences

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 11, 2022--Regulatory News:

NANOBIOTIX (Euronext : NANO — NASDAQ: NBTX – the "**Company**"), a clinical-stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that Laurent Levy, co-founder and chairman of the executive board, and Bart Van Rhijn, chief financial officer, will participate in the following conferences:

UBS Global Healthcare Conference

- Presentation Date: Monday, May 23rd, 2022
- Time: 10:45 AM ET
- Location: New York, New York, USA

H.C. Wainwright Global Investment Conference

- Presentation Date: Wednesday, May 25th, 2022
- Time: 8:30 AM ET
- Location: Virtual and Miami, Florida, USA

A live audio webcast of each presentation will be available on the events page of the Investors section of the Company's website. A replay will be available on the Nanobiotix website within 48 hours after each event. The Company's corporate presentation can be downloaded here.

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The company's philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France. The company also has subsidiaries in Cambridge, Massachusetts (United States), France, Spain, and Germany.

Nanobiotix has been listed on the regulated market of Euronext in Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020.

Nanobiotix is the owner of more than 30 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system. The company's resources are primarily devoted to the development of its lead product candidate—NBTXR3—which is the product of its proprietary oncology platform and has already achieved market authorization in Europe for the treatment of patients with soft tissue sarcoma under the brand name Hensify®.

For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.

Contacts

Nanobiotix

Communications Department

Brandon Owens

VP, Communications

+1 (617) 852-4835

contact@nanobiotix.com

Investor Relations Department

Kate McNeil

SVP, Investor Relations

+1 (609) 678-7388

investors@nanobiotix.com

Media Relations

FR – Ulysse Communication

Pierre-Louis Germain

+33 (0) 6 64 79 97 51

plgermain@ulyse-communication.com

US – **Porter Novelli**

Caitlin Hunt

+1 (781) 985-5967

Caitlin.hunt@porternovelli.com